Literature DB >> 2687764

Identification of alternatively spliced transcripts for human c-myb: molecular cloning and sequence analysis of human c-myb exon 9A sequences.

P Dasgupta1, E P Reddy.   

Abstract

The murine c-myb gene has been recently shown to code for two protein products of 75kd and 89kd. The 89kd protein appears to be generated from an alternatively spliced mRNA which contains an additional stretch of 363 bases between exons 9 and 10. In this communication, we have examined whether similar alternatively spliced mRNAs of c-myb occur in human cells. Human c-myb exon 9A has been identified and sequenced in a cDNA clone (ML5) generated from the acute myeloid leukemic cell line ML-2. This alternatively spliced exon of c-myb has been found to contain the same number of nucleotides (363bp) as the corresponding mouse exon. Between murine and human exon 9A sequences, 81% sequence homology was found at the DNA level, while the homology at the predicted amino acid level was found to be 73%. A stretch of 14 amino acid residues at the junction of exons 9A and 10 have been found to be conserved between Drosophila and human sequences indicating that this region might perform an essential biological function which was deemed necessary through evolution.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2687764

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  14 in total

1.  Evolutionary conservation of alternative splicing in chicken.

Authors:  S Katyal; Z Gao; R-Z Liu; R Godbout
Journal:  Cytogenet Genome Res       Date:  2007       Impact factor: 1.636

2.  Role of c-Myb in the survival of pre B-cell acute lymphoblastic leukemia and leukemogenesis.

Authors:  Purvaba J Sarvaiya; Jason R Schwartz; Claudia P Hernandez; Paulo C Rodriguez; Wayne V Vedeckis
Journal:  Am J Hematol       Date:  2012-07-05       Impact factor: 10.047

3.  p89c-Myb is not required for fetal or adult hematopoiesis.

Authors:  Stacey J Baker; Atul Kumar; E Premkumar Reddy
Journal:  Genesis       Date:  2010-05       Impact factor: 2.487

4.  Alternative splicing of RNAs transcribed from the human c-myb gene.

Authors:  G L Shen-Ong; R M Skurla; J D Owens; J F Mushinski
Journal:  Mol Cell Biol       Date:  1990-06       Impact factor: 4.272

5.  Recurrent fusion of MYB and NFIB transcription factor genes in carcinomas of the breast and head and neck.

Authors:  Marta Persson; Ywonne Andrén; Joachim Mark; Hugo M Horlings; Fredrik Persson; Göran Stenman
Journal:  Proc Natl Acad Sci U S A       Date:  2009-10-19       Impact factor: 11.205

6.  Molecular mechanisms associated with the regulation of apoptosis by the two alternatively spliced products of c-Myb.

Authors:  Atul Kumar; Stacey J Baker; Clement M Lee; E Premkumar Reddy
Journal:  Mol Cell Biol       Date:  2003-09       Impact factor: 4.272

7.  Overexpression of an alternatively spliced form of c-Myb results in increases in transactivation and transforms avian myelomonoblasts.

Authors:  C H Woo; L Sopchak; J S Lipsick
Journal:  J Virol       Date:  1998-08       Impact factor: 5.103

8.  More on Myb in myelofibrosis: molecular analyses of MYB and EP300 in 55 patients with myeloproliferative disorders.

Authors:  David P Steensma; Animesh Pardanani; William S Stevenson; Rosemary Hoyt; Hiu Kiu; Andrew P Grigg; Jeff Szer; Surender Juneja; Douglas J Hilton; Warren S Alexander; Andrew W Roberts
Journal:  Blood       Date:  2006-02-15       Impact factor: 22.113

9.  Alternative RNA splicing produces multiple forms of c-Myb with unique transcriptional activities.

Authors:  John P O'Rourke; Scott A Ness
Journal:  Mol Cell Biol       Date:  2008-01-14       Impact factor: 4.272

10.  An isoform-specific mutation in the protein 4.1 gene results in hereditary elliptocytosis and complete deficiency of protein 4.1 in erythrocytes but not in nonerythroid cells.

Authors:  J G Conboy; J A Chasis; R Winardi; G Tchernia; Y W Kan; N Mohandas
Journal:  J Clin Invest       Date:  1993-01       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.